Mention “health insurance stocks” at a Wall Street cocktail party right now, and you’ll likely clear the room.
Nobody wants to touch this beaten-down sector. UnitedHealth Group (UNH) has been cut in half from its highs, and sentiment across the industry is colder than a hospital waiting room. Over the last two years, a cascade of headwinds—from volatile political rhetoric to a sudden spike in claims costs—has knocked over the dominoes. Investors have fled for the hills of AI plays or safety trades, leaving health insurers groaning in the corner.
But as the legendary investor Sir John Templeton once observed: “Bull markets are born on pessimism.” When an asset class becomes the target of universal derision and abandonment, that is precisely when long-term capital should start paying attention. Beneath the surface of this despised sector lies an investment thesis backed by a staggering $5.3 trillion wall of rigid spending.
UnitedHealth, the behemoth with a towering $448 billion in annual revenue, is navigating a rare period of acute pain. The company has been battered not only by the fallout from a major cyberattack but also by severe operational headwinds. Last year, its Medical Loss Ratio (MLR)—the percentage of premiums paid out in claims—climbed from 85.5% to 88.9%. In plain English: nearly ninety cents of every dollar collected in premiums went right back out the door. The result? Earnings plunged 41% year-over-year.
The market’s punishment has been swift and merciless. A stock once cradled as a premier blue chip now trades at a compressed price-to-earnings (P/E) ratio of 23.5, a steep discount to broader market averages.
Yet, this is where the line between sentiment and value is drawn. The masses see declining profits and endless political squabbling. The contrarians see a subtle but crucial thaw in the regulatory landscape. Recent signals indicate that regulators are offering a more generous-than-expected rate increase for Medicare Advantage plans in 2027. For a giant like UnitedHealth, the math is simple: if you can push pricing just a little higher and squeeze that Medical Loss Ratio back down by even a percentage point or two, the massive revenue base turns that minor operational tweak into explosive earnings recovery. At current levels, the stock isn’t pricing in the present reality; it’s pricing in a worst-case scenario that may never fully materialize.
If UnitedHealth represents the restoration of an empire, Oscar Health (OSCR) represents a scrappy insurgency.
This tech-forward insurer, focused squarely on the Affordable Care Act (ACA) individual marketplace, has seen its share price battered just as badly as the incumbents. But the underlying business logic hasn’t died—it has been quietly swelling in size. Membership has skyrocketed from under 1 million at the end of 2021 to 3.4 million by the start of 2026. Achieving that kind of growth in a market segment that has been kicked around like a political football is a testament to the company’s resonance with consumers.
Oscar’s edge is the user experience. The company is attempting to make the act of dealing with a health insurer feel less like a bureaucratic fistfight and more like a seamless tech interaction. While an MLR of 87.4% still weighs heavily on the bottom line, scale is beginning to kick in. Management is projecting operating income of $250 million to $450 million for 2026. For a company with a market capitalization hovering around just $4.3 billion, the moment profitability flips positive, the multiple expansion story becomes a compelling one.
Strip away the near-term volatility of the stock ticker and look at the most banal, inexorable fact: America is getting older, and healthcare is only getting more expensive.
In 1970, total U.S. healthcare spending was a mere $74 billion. By 2024, that figure had ballooned to an astronomical $5.3 trillion. This is not a speculative bubble; it is the rigid arithmetic of demographics and life-saving innovation. Whether it’s a six-figure gene therapy or a routine surgery, that torrent of spending must eventually flow through the plumbing of the health insurance ecosystem.
Political winds shift with the election cycle, but demographic shifts and disease prevalence move with the slow, crushing force of tectonic plates. The current market panic is the result of investors squinting through a microscope at a single quarter’s claims data in 2025, while completely ignoring the telescope view of 2026 rate adjustments and the aging population wave.
When the “Great Rotation” wind finally catches this sector in 2026, when UnitedHealth’s MLR peaks and rolls over, and when Oscar Health’s scale crosses the threshold of profitability, the same capital that walked away in disgust today will likely come rushing back in a fit of anxiety tomorrow.
Doing the homework while others are cursing the darkness, and placing the bet while others have forgotten the name—that is perhaps the most elegant posture for a long-term investor facing this coming rotation.
